Skip to main content

Table 1 Characteristics asthmatic patients’

From: Angiopoietin-2 concentration in serum is associated with severe asthma phenotype

  Non severe asthma Severe/refractory asthma Statistical significance (p)
Number of patients 51 45  
Age (years) 39.82 ± 2 51.13 ± 2.1 p < 0.01
Female/male 27/24 31/14 Ns
Atopy (%) 43 (84 %) 37 (82 %) Ns
Duration of asthma (years) 11.7 ± 1.4 21.7 ± 1.8 Ns
Aspirin hypersensitivity (%) 12 (24 %) 12 (27 %) Ns
Nasal polyps 15 (29 %) 11 (24 %) Ns
BMI 24.8 ± 0.58 27.60 ± 0.7 Ns
FEV1 (% of predicted) 99.7 ± 2.06 69.8 ± 2.9 p < 0.05
FEV1/FVC % 78.1 ± 1.4 61.4 ± 1.9 p < 0.001
MEF 25-75 (% of predicted) 83.9 ± 4 38.9 ± 2.8 p < 0.001
FEV1 reversibility (%) 8.41 ± 0.99 21.7 ± 2 P < 0.001
Mean dose inhaled GCS (µg budesonide) 617 ± 35 2006 ± 42 p < 0.001
No of patients on oral GCS 0 26 (58 %) p < 0.001
Mean dose of oral GCS (mg prednisone per day) 0 4.24 ± 0.7 p < 0.001
Mean number of exacerbation during 12 months 0.51 ± 0.08 1.5 ± 0.12 p < 0.001
Mean number of interventions of emergency service 0 0.18 ± 0.05 p < 0.001
Mean number of hospitalizations during last 12 months 0 0.17 ± 0.05 p < 0.001
ECP (µg/l) 9.59 ± 1.2 15.78 ± 2.6 p = 0.04
Total IgE (kU/l) 200 ± 33.9 348 ± 72.7 p = 0.03
  1. Data presented as mean ± SEM
  2. BMI body mass index, FEV 1 forced expiratory volume in 1 s, FVC forced vital capacity, GCS glucocorticosteroids, MEF maximum expiratory flow